Decibel Therapeutics (NSDQ:DBTX) recently presented preclinical data for DB-OTO at the Annual MidWinter Meeting of the Association for Research in Otolaryngology (ARO).
DB-OTO is a dual-vector adeno-associated virus (AAV) investigational gene therapy product candidate for individuals with hearing loss from mutations of the otoferlin gene.
The most recent data showed that otoferlin expression increased for several weeks before plateauing, which was in line with prior research involving mice that achieved stable, functional recovery.
Prior preclinical research found that DB-OTO restored functional otoferlin protein in mice and dose scaling and distribution in non-human primates.
A Phase 1/2 trial is planned for DB-OTO in sensorineural hearing loss.
Also at ARO, the company presented data on proprietary, cell-selective promoters for three of its gene therapy pipeline candidates.
DBTX shares ticked up about 1% to $4.30.
In September, Decibel Therapeutics announced the publication of a study in Cell on noise-related inner ear damage that involved its data.
Filed Under: ENT drugs